06826 HAOHAI BIOTEC
- 27.250
- +0.700+2.64%
HAOHAI BIOTEC News
haohai biotec (06826.HK) spent 0.3132 million Hong Kong dollars on November 21 to repurchase 0.011 million shares.
Grondlon November 21st | haohai biotec (06826.HK) announced that on November 21, 2024, it will spend 0.3132 million Hong Kong dollars to repurchase 0.011 million shares at a repurchase price of 28.4-28.55 Hong Kong dollars per share.
Huachuang Securities: The retail and social services sectors are experiencing a rebound in customer traffic, with both fundamentals and valuation recovering.
Looking ahead to 2025, the service consumer sector is experiencing a rapid turnaround and repair, with both the 'broad and profound' fundamentals and valuation repair taking effect, establishing a clear trend.
haohai biotec (06826.HK) spent 0.3102 million Hong Kong dollars on November 20 to repurchase 0.0108 million shares.
Gelonghui November 20th | haohai biotec (06826.HK) announced that on November 20, 2024, it spent 0.3102 million Hong Kong dollars to repurchase 0.0108 million shares at a repurchase price of 28.7-28.75 Hong Kong dollars per share.
Intelligent Hong Kong Stock Repurchase Statistics | November 20th
Hong Kong Stock Buyback Statistics | November 20th
On November 19, haohai biotec (06826.HK) spent 0.5506 million Hong Kong dollars to repurchase 0.0193 million shares.
Gelonghui, on November 19, announced that haohai biotec (06826.HK) spent 0.5506 million Hong Kong dollars to repurchase 0.0193 million shares on November 19, 2024, with a repurchase price of 28.4-28.6 Hong Kong dollars per share.
Zhijing Hong Kong Stocks Buyback Statistics | November 19th
Hong Kong stock repurchase statistics | November 19th
Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) Share Price Is Still Matching Investor Opinion Despite 26% Slump
[Brokerage Focus] Dongbei Securities maintains a 'buy' rating on haohai biotec (06826), indicating that its market share is expected to increase year by year.
Kingwu Financial News | Dongbei Securities issued a research report, haohai biotec (06826) has a strong medical academic background, coupled with increasing research and development investment, steadily enhancing technological advantages, and the effectiveness of hyaluronic acid products has been continuously verified and widely recognized in the market. The first generation "Haiwei" and the second generation "Jiaolan" continue to maintain steady growth, while the third generation "Hai Mei" and "Hai Mei Yun" establish a high-end brand image. The fourth generation "Hai Mei. Yuebai" pioneered organic cross-linking of hyaluronic acid, strengthening its high-end brand position, while differentiating from the previous three generations in terms of functional features and price positioning of hyaluronic acid, meeting diversified medical and aesthetic demands. The bank stated that the company's vision
We Think That There Are Issues Underlying Shanghai Haohai Biological Technology's (HKG:6826) Earnings
haohai biotec (06826) has not yet implemented the second phase of share buyback as of the end of October.
haohai biotec (06826) announced that, according to the Rules on Share Repurchase of Listed Companies, Shanghai Stock Exchange...
shanghai haohai biological technology (688366.SH): has not yet implemented the second phase of share repurchase
On October 31st, Gelonhui reported that shanghai haohai biological technology (688366.SH) announced that as of October 31, 2024, the company has not yet implemented the second phase of share repurchase.
Haohai biotec (06826.HK) completed the cancellation of 0.8057 million H shares
On October 30th, GeLongHui announced that Haohai Biotec (06826.HK) has completed the cancellation of 805,700 H股 shares repurchased on October 30, 2024. After the cancellation, the company's total share capital has changed from 234,995,995 shares to 234,190,295 shares.
haohai biotec (06826): Lou Guoliang did not reduce the company's shareholding, and the shareholding plan has been completed.
haohai biotec (06826) announced that the company received a letter from Lou Guoliang on October 29, 2024...
haohai biotec (06826.HK) spent 6.044 million Hong Kong dollars on October 29 to repurchase 0.2 million shares.
On October 29, haohai biotec (06826.HK) announced that it repurchased 0.2 million shares for a total of 6.044 million Hong Kong dollars on October 29th.
After the third quarter report, the stock price fell by more than 12%, who can save haohai biotec (06826) in ophthalmology and medical aesthetics?
Although from October 16th to October 25th, haohai biotec's Hong Kong stock price entered a consolidation phase along with the overall market and began to slowly recover, a quarterly report released after the market on the 25th seems to signal the company being dragged into the next round of downward trends.
Shanghai Haohai Biological Technology Posts 13% Drop in Q3 Profit
Hong Kong stock market anomaly | haohai biotec (06826) fell more than 8% after the performance, third-quarter results lower than expected, research and development investment continues to increase.
haohai biotec (06826) fell more than 8% after the performance announcement. As of the deadline, it fell by 8.41%, closing at 31.05 Hong Kong dollars, with a turnover of 8.256 million Hong Kong dollars.
Shanghai Haohai Biotechnology Co., Ltd. Report for the Third Quarter of 2024
Shanghai Haohai Biological Technology (688366.SH) released its performance for the first three quarters, with a net income of 0.341 billion yuan, a year-on-year increase of 4.31%.
shanghai haohai biological technology (688366.SH) disclosed the third quarter report for 2024, achieving revenue in the first three quarters of the company...
Shanghai Haohai Biological Technology (688366.SH): The net income in the first three quarters was 0.34 billion yuan, a year-on-year increase of 4.31%.
GeLongHui October 25th | Shanghai Haohai Biological Technology (688366.SH) released its third quarter report, with a revenue of 2.07 billion yuan in the first three quarters, a year-on-year increase of 4.69%; net income of 0.34 billion yuan, a year-on-year increase of 4.31%; non-GAAP net income of 0.321 billion yuan, a year-on-year increase of 5.53%; and basic earnings per share of 1.46 yuan.
Analysis
Price Target
No Data
No Data